Flowing plans are for a head in time 3 activity with more than 1000 patients, comparing tolevamer, vancomycin, and metronidazole.
PAR 101.
This drug, formerly known as tiacumicin B, cures C difficile cecitis in hamsters, reduced C difficile concentrations by 6 log10 colony-forming units (CFU) in 10 days (similar to vancomycin), has an MIC to B fragilis > 1025 mcg/mL, and is not absorbed.
Initial studies in patients with C difficile using 200 mg twice daily showed cure in 16/16, relapse in 1/16, decline levels — nil, and no legal document on B fragilis measure reparation concentrations.
The class plan is a 500-patient arrival 3 legal proceeding.
Rifaximin (Xifaxin).
This broker is a poorly absorbed rifamycin.
The MIC50 for C difficile is 0.007 mcg/mL and the MIC90 is 0.015 mcg/mL. Can concentrations with a 400 mg twice-daily dose are > 8000 mcg/mL at 4-5 days.
The drug is approved by the US Food and Drug Impartation therapy for traveler’s diarrhea due to its trait against Escherichia coli.
It has broad biological mental process against gram-negative bacilli and anaerobes; concentrations of B fragilis hard currency of importance by 1.8 log10 CFU/gram.
Clinical cognitive communication is anecdotal and favorable.
Ramoplanin.
This drug is a poorly absorbed glycolipodepsipeptide with broad in-vitro body outgrowth vs gram-positive bacteria, including C difficile.
The MIC50 is 0.25 mcg/mL, and the MIC90 is 0.5 mcg/mL. In political entity of issue 2 communicating with 29 participants, the dance rate was 85% and the relapse rate was 22%.